Immunocore Holdings plc (NASDAQ:IMCR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Immunocore Holdings plc (NASDAQ:IMCR) has been given a consensus recommendation of “Moderate Buy” by the thirteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $65.64.

A number of equities research analysts have issued reports on IMCR shares. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and cut their target price for the company from $72.00 to $38.00 in a research note on Monday, November 11th. UBS Group initiated coverage on shares of Immunocore in a research report on Thursday, October 24th. They issued a “sell” rating and a $24.00 price objective on the stock. Morgan Stanley restated an “equal weight” rating and issued a $35.00 target price (down previously from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price target on shares of Immunocore in a report on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Monday.

Institutional Investors Weigh In On Immunocore

Institutional investors and hedge funds have recently bought and sold shares of the business. Envestnet Asset Management Inc. lifted its stake in Immunocore by 0.9% during the second quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company’s stock valued at $2,392,000 after purchasing an additional 606 shares during the last quarter. Squarepoint Ops LLC lifted its position in shares of Immunocore by 2,265.8% during the 2nd quarter. Squarepoint Ops LLC now owns 73,766 shares of the company’s stock valued at $2,500,000 after acquiring an additional 70,648 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Immunocore by 124.4% during the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock worth $20,366,000 after acquiring an additional 333,167 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Immunocore by 37.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 121,753 shares of the company’s stock worth $4,126,000 after acquiring an additional 33,003 shares during the last quarter. Finally, Connective Portfolio Management LLC acquired a new stake in shares of Immunocore during the third quarter worth $218,000. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Trading Down 1.4 %

NASDAQ IMCR opened at $31.64 on Thursday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore has a one year low of $27.69 and a one year high of $76.98. The company has a 50-day simple moving average of $30.53 and a 200-day simple moving average of $33.22. The firm has a market capitalization of $1.58 billion, a PE ratio of -33.30 and a beta of 0.76.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business’s revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.59) earnings per share. On average, equities analysts forecast that Immunocore will post -0.94 earnings per share for the current year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.